Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Surgery
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 28 Days to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2035
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Chemotherapy, SBRT, Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Baltimore, Maryland • Bel Air, Maryland • Glen Burnie, Maryland

Conditions: Hypertension
Interventions: Technology-enabled Team Care, Enhanced Usual Care; Other
Lead sponsor: East Carolina University; Other
Eligibility: 19 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Greenville, North Carolina • Wilmington, North Carolina

Conditions: COVID, Corona Virus Infection, COVID19
Interventions: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more

Conditions: Glioblastoma Multiforme
Interventions: MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Stanton Gerson MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: 18F-FHBG, Aldesleukin, Cellular Therapy, Computed Tomography, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, Leukapheresis, Melphalan, Plerixafor, Positron Emission Tomography; Radiation · Biological · Procedure + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Cancers
Interventions: Gene Modified T Cells; Genetic
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions: Ranger blood warmer (3M Healthcare, Oakdale, Minnesota); Device
Lead sponsor: University of South Carolina; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Breast Cancer
Interventions: Pre-Visit Patient Text Message, Post-Visit Patient Text Messages, Smart Data Element (SDE); Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 40 Years to 74 Years · Female only
Enrollment: 8,490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF; Procedure · Drug · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: bleomycin, Ommaya reservoir, radiation therapy; Biological · Device · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 13
States / cities: Phoenix, Arizona • Lexington, Kentucky • Omaha, Nebraska + 10 more

Conditions: HIV, HIV Infections
Interventions: ZFN modified T cells, Structured Treatment Interruption; Biological · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: The Bronx, New York • Philadelphia, Pennsylvania

Conditions: Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions: Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator; Behavioral · Device · Biological + 1 more
Lead sponsor: Noah Tech, Corp.; Industry
Eligibility: 55 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palisades Park, New Jersey

Conditions: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions: Iberdomide, CAR-T Leukapheresis, CAR-T Infusion; Drug · Procedure
Lead sponsor: Shambavi Richard; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions: Radiation Therapy (IMRT or IMPT); Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Interventions: EndeavorRx; Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, Progressive
Interventions: Amniotic fluid or placental CD117 stem cells; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Melanoma
Interventions: Dose 1, Dose 2, Dose 3, Dose 4; Biological
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Allogeneic Mesenchymal Precursor Cells, Normal Saline; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 20
States / cities: Anniston, Alabama • Gilbert, Arizona • El Cajon, California + 17 more

Conditions: Protruded Disk
Interventions: CLARIX™100, CLARIX CORD 1K; Other
Lead sponsor: Amniox Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bensalem, Pennsylvania

Conditions: Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions: Red blood cell transfusion; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 6 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Lung Cancer
Interventions: Metformin, Placebo, Stereotactic body Radiotherapy (SBRT); Drug · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiac Surgery, Blood Transfusion, Anemia, Cardiopulmonary Bypass
Interventions: Demand-Informed Transfusion Decision Rule; Other
Lead sponsor: Yan Mia Min; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Feeding Tolerance
Interventions: Probiotic Supplemented Group, Control Group; Dietary Supplement
Lead sponsor: Mercy Health System; Network
Eligibility: Up to 14 Days
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rockford, Illinois

Search by objective public record fields.

Establishment of Cell Culture Systems From Discarded Operating Room Tissue

A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

Heart to Heart: BP Control Partners

hCT-MSCs for COVID19 ARDS

BG & TMZ Therapy of Glioblastoma Multiforme

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

Blood Warming in Preterm Infants to Decrease Hypothermia

Increasing Screening for Cancer Using EHR-Nudges Replication

Cord Blood Expansion on Mesenchymal Stem Cells

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

Metformin in Non Small Cell Lung Cancer (NSCLC)

Personalized Blood Transfusion Protocol for Cardiac Patients

The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants